Everything below concerns Epithalamin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Identity confirmation uses mass spectrometry, usually electrospray ionisation in positive mode or matrix-assisted laser desorption. The protonated free peptide produces a signal near three hundred and ninety-one daltons, while salt adducts shift that value slightly. Tandem mass spectrometry or amino acid analysis supplies sequence-level confirmation, which a single mass measurement cannot. Peptides containing aspartate can cyclise into succinimide intermediates that hydrolyse to isoaspartate isomers of identical mass. Because those isomers are difficult to separate chromatographically, identity and purity results carry more weight when interpreted together.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Tetrapeptide, often abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free peptide, unmodified termini |
| Molecular weight | ~390.35 Da | Calculated for the free acid form |
| Appearance | White to off-white powder | Typical lyophilized product form |
| Solubility class | Freely soluble in water | Two acidic residues dominate ionic character |
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
==== Merger ==== Glaxo and Wellcome merged in 1995, to form Glaxo Wellcome plc. The merger was then considered the biggest in the UK corporate history. Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening a Medicines Research Centre in Stevenage, Hertfordshire. Also that year, Glaxo Wellcome acquired the California-based Affymax, a leader in the field of combinatorial chemistry. By 1999, Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent. Its products included Imigran (for the treatment of migraine), salbutamol (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). In 1999, the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS. It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among the world's top 50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent, London and Verona (Italy), and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East.
Davis who developed and patented of the real-time single particle mass spectrometry (RTSPMS) instrument. The setup is quite similar to today's AMS system, with the sample being introduced through a small steel capillary into the ion source region. The sample would ionize after striking a hot rhenium filament. The resulting ions were separated in a magnetic sector and detected by an electron multiplier. The method could only ionize elements with ionization potentials below the work function of the filament (~8 eV), typically alkali and alkaline earth metal. The instrument did yield unit resolution up to a mass-to-charge ratio of 115. The RTSPMS instrument had a particle transmission/detection efficiency of 0.2-0.3%. Davis used the RTSPMS instrument to study samples from calibration aerosols, ambient laboratory air, and aerosols sources. Majority of his studies where focused on inorganic salts created in lab. In Davis's analysis of ambient air, he found a significant increase in lead at the end of the day, which was concluded to be due to automobile emissions. This development was the first step towards, today's modern on-line instruments. The next major development in technological improvement that came out of the 1970s was in 1976 by Stoffel with the development of a magnetic sector RTSPMS technique that had a direct-inlet mass spectrometry (DIMS) also known as particle-inlet mass spectrometry (PIMS).
FGL's other holdings include: Flagler Station – Located off the Florida Turnpike and NW 106th Street in Miami, Flagler Station is the state's largest business park, with direct access to the Florida East Coast Railway. The facility has been built in phases. FGL is developing the third and final phase, which will include 1.7 million square feet of new warehouse and distribution space and is scheduled to come online in 2015. When finished, the park will hold more than 10 million square feet of business, commercial, and industrial space. Flagler Station is an approved magnet site for Foreign Trade Zone No. 281. Its tenants include Ryder System, FedEx, Crowley, and Carrier. Titusville Logistics Center – The facility is located on 200 acres that were part of the original Florida East Coast Railway's land holdings. The site features nearly a mile of land directly adjacent to the FECR mainline. The land is permitting for more than 3 million square feet of Class A warehouse and distribution space when the phased build out is complete. To support its growing cargo business, the Canaveral Port Authority recently leased 246,240 square feet of space at the Titusville Logistics Center.
Sources: en.wikipedia.org
non-coding RNA (ncRNA) Any molecule of RNA that is not ultimately translated into a protein. The DNA sequence from which a functional non-coding RNA is transcribed is often referred to as an "RNA gene". Numerous types of non-coding RNAs essential to normal genome function are produced constitutively, including transfer RNA (tRNA), ribosomal RNA (rRNA), microRNA (miRNA), and small interfering RNA (siRNA); other non-coding RNAs (sometimes described as "junk RNA") have no known function and are likely the product of spurious transcription.
Following the Molotov–Ribbentrop Pact of 1939, in June 1940 Romania accepted the loss of Bessarabia, Northern Bukovina and the Hertsa region in favour of the USSR (as stipulated in the Soviet ultimatum of 28 June 1940). Unaware of the details of the Soviet–German pact, Carol attempted to secure an alliance with Nazi Germany, and appointed Ion Gigurtu as President of the Council of Ministers, who declared that he would pursue a Nazi pro-Axis (Berlin–Rome) policy that was anti-Semitic and fascist-totalitarian in nature. Between 4 July and 4 September 1940, by accepting Hitler's arbitration over Transylvania (after Gigurtu declared on radio that Romania must make territorial sacrifices to justify its Nazi orientation and full adherence to the Berlin–Rome Axis), Romania ceded Northern Transylvania—including the city of Cluj—to Hungary. The vast territories in Transylvania ceded by Ion Gigurtu to Hungary contained important natural resources, including gold mines. Ion Gigurtu also initiated negotiations to cede 8,000 km2 of Southern Dobruja to Bulgaria, these negotiations were interrupted by Antonescu's unconditional acceptance of the territorial cession. In response to the chaotic withdrawal from Bessarabia, the territorial cessions, public discontent, and protests from political leaders, King Carol II suspended the 1938 Constitution of Romania and appointed General Ion Antonescu as Prime Minister. This measure, supported by the Iron Guard, demanded that the king abdicate in favour of his son, Mihai.
The Netherlands Ministry of Education funds most public universities. Dutch citizens and those from European Union countries pay an annual tuition fee for their first bachelor's or master's degree; the fee was €1,951 in 2015. Non-European Union students and students who want to complete a second bachelor's or master's degree pay a legal school fee. Annually, these legal school fees range between €7,000 for bachelor programs and €30,000 for master's programs in medicine. The Ministry of Education supervises all universities, including private institutions.
Sources: en.wikipedia.org
Static light scattering and dynamic light scattering use light to determine the average molecular weight and behavior of the copolymer in solution whereas small-angle neutron scattering uses neutrons to determine the molecular weight and chain length. Additionally, x-ray scattering techniques, such as small-angle X-ray scattering (SAXS) can help determine the nanometer morphology and characteristic feature size of a microphase-separated block-copolymer or suspended micelles. Differential scanning calorimetry is a thermoanalytical technique used to determine the thermal events of the copolymer as a function of temperature. It can indicate when the copolymer is undergoing a phase transition, such as crystallization or melting, by measuring the heat flow required to maintain the material and a reference at a constantly increasing temperature. Thermogravimetric analysis is another thermoanalytical technique used to access the thermal stability of the copolymer as a function of temperature. This provides information on any changes to the physicochemical properties, such as phase transitions, thermal decompositions, and redox reactions. Size-exclusion chromatography can separate copolymers with different molecular weights based on their hydrodynamic volume. From there, the molecular weight can be determined by deriving the relationship from its hydrodynamic volume. Larger copolymers tend to elute first as they do not interact with the column as much.
Some 3.3 V vaping devices using low-resistance heating elements such as an ohm of 1.5, containing 36 mg/mL liquid nicotine can obtain blood nicotine levels after 10 puffs that may be higher than with traditional cigarettes. A 2015 study evaluated "a variety of factors that can influence nicotine yield and found that increasing power output from 3 to 7.5 W (an approximately 2.5-fold increase), by increasing the voltage from 3.3 to 5.2 V, led to an approximately 4- to 5-fold increase in nicotine yield." A 2015 study, using a model to approximate indoor air workplace exposure, anticipates greatly reduced exposure to nicotine from e-cigarettes than traditional cigarettes. A 2016 World Health Organization (WHO) report found "nicotine in SHA [second-hand aerosol] has been found between 10 and 115 times higher than in background air levels." A 2015 Public Health England (PHE) report concluded that e-cigarettes "release negligible levels of nicotine into ambient air". A 2016 Surgeon General of the United States report stated that the exposure to nicotine from e-cigarette vaping is not negligible and is higher than in non-smoking environments. Vaping generates more surrounding air levels of particulate matter and nicotine in indoor areas than background air levels. Extended indoor e-cigarette use in rooms that are not sufficiently ventilated could surpass occupational exposure limits to the inhaled metals. The e-cigarette vapor may also contain tiny amounts of toxicants, carcinogens, and heavy metals.
The antisense oligonucleotide golodirsen (Vyondys 53) was approved for medical use in the United States in 2019, for the treatment of cases that can benefit from skipping exon 53 of the dystrophin transcript. The Morpholino antisense oligonucleotide viltolarsen (Viltepso) was approved for medical use in the United States in August 2020, for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Developed by Nippon Shinyaku and the National Center of Neurology and Psychiatry (NCNP), viltolarsen's pre-clinical development was supported by pioneering work from Toshifumi Yokota and colleagues. It is the second approved targeted treatment for people with this type of mutation in the United States. Approximately 8% of people with DMD have a mutation that is amenable to exon 53 skipping. Casimersen (Amondys 45) was approved for medical use in the United States in February 2021, and it is the first FDA-approved targeted treatment for people who have a confirmed mutation of the Duchenne muscular dystrophy gene that is amenable to exon 45 skipping. Comprehensive multidisciplinary care guidelines for Duchenne muscular dystrophy have been developed by the US Centers for Disease Control and Prevention and were published in 2010. An update was published in 2018. Delandistrogene moxeparvovec (Elevidys) is a gene therapy that in June 2023 received United States FDA accelerated approval for the treatment of four and five-year-old children.
Sources: en.wikipedia.org
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.
No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.
The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.
Reversed-phase high-performance liquid chromatography with ultraviolet detection at 214 nanometres is the usual approach. Peak area percentage provides a purity figure relative to other components in the sample. Mass spectrometry is then applied to confirm identity.